Recombinant Human Tumor necrosis factor receptor superfamily member 13B protein (TNFRSF13B), partial (Active)
Shipped with Ice Packs 
In Stock 
Description
Overview of TNFRSF13B and Recombinant Protein
TNFRSF13B, also known as TACI (transmembrane activator and CAML interactor) or CD267, is a lymphocyte-specific receptor in the TNF superfamily. It binds ligands BAFF (B cell-activating factor) and APRIL (a proliferation-inducing ligand), playing a critical role in B-cell development, antibody class switching, and plasma cell differentiation . Recombinant TNFRSF13B proteins are engineered to study these functions in vitro and in vivo.
The "partial (Active)" designation refers to truncated versions of the protein that retain functional extracellular domains (ECD) while omitting non-essential regions. These constructs are optimized for bioactivity assays or therapeutic applications.
Expression Systems
Key Differences
-
Glycosylation: HEK293-derived proteins retain eukaryotic post-translational modifications, enhancing ligand binding .
-
Activity: E. coli-produced versions demonstrate functional blocking of BAFF-induced cell survival .
Bioactivity Assays
-
ED50 Range: 3–10 ng/mL for inhibiting T cell-independent antibody responses .
-
Plasma Cell Differentiation: Defective Blimp-1 synthesis in TNFRSF13B-deficient B cells .
Immunological Studies
| Model | Observation | Source |
|---|---|---|
| TACI-KO Mice | Defective T-independent antibody responses; reduced IgA production | |
| Human CVID | Biallelic mutations (e.g., S144X) correlate with impaired APRIL binding |
Comparative Analysis of Recombinant Forms
| Form | Advantages | Limitations | Source |
|---|---|---|---|
| HEK293-Derived | Native glycosylation; high purity | Higher cost; complex production | |
| E. coli-Derived | Cost-effective; rapid production | Lack eukaryotic modifications |
Clinical and Therapeutic Relevance
-
Immunodeficiency: Mutations in TNFRSF13B are linked to common variable immunodeficiency (CVID) and selective IgA deficiency .
-
Therapeutic Target: Recombinant TNFRSF13B proteins may modulate BAFF/APRIL signaling in autoimmune diseases or immunodeficiencies .
Critical Research Findings
Product Specs
Buffer
Lyophilized from a 0.2 µm filtered PBS, pH 7.4
Description
This Recombinant Human TNFRSF13B (CD267) protein is a valuable research tool in the field of cancer research. TNFRSF13B, also known as Transmembrane activator and CAML interactor (TACI), is a member of the tumor necrosis factor receptor superfamily and plays a crucial role in immune regulation and B-cell development.
Our protein, produced using an E. coli expression system, encompasses amino acids 1 to 160, representing a partial length of the TNFRSF13B sequence. It is tag-free, ensuring its native conformation and eliminating potential interference in downstream applications. With a purity exceeding 95% and minimal endotoxin contamination, our TNFRSF13B protein guarantees reliable and consistent results.
Demonstrating full biological activity when compared to standards, this protein effectively blocks human BAFF-induced T2B cell survival. Our protein exhibits potency in cancer-related studies, with a concentration range of 1.0-3.0 µg/ml. The lyophilized powder form simplifies handling and storage, offering convenience for your research endeavors.
Form
Lyophilized powder
Lead Time
5-10 business days
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Reconstitution
We recommend centrifuging the vial briefly before opening to ensure the contents settle at the bottom. Reconstitute the protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. For long-term storage, we advise adding 5-50% glycerol (final concentration) and aliquoting at -20°C/-80°C. Our default final concentration of glycerol is 50% and can be used as a reference.
Shelf Life
The shelf life is influenced by various factors, including storage conditions, buffer ingredients, storage temperature, and the stability of the protein itself.
Generally, the liquid form has a shelf life of 6 months at -20°C/-80°C. Lyophilized form can be stored for 12 months at -20°C/-80°C.
Generally, the liquid form has a shelf life of 6 months at -20°C/-80°C. Lyophilized form can be stored for 12 months at -20°C/-80°C.
Storage Condition
Store at -20°C/-80°C upon receipt. Aliquoting is necessary for multiple uses. Avoid repeated freeze-thaw cycles.
Tag Info
Tag-Free
Synonyms
TNFRSF13B; TACI; Tumor necrosis factor receptor superfamily member 13B; Transmembrane activator and CAML interactor; CD antigen CD267
Datasheet & Coa
Please contact us to get it.
Expression Region
1-160aa
Mol. Weight
18.0 kDa
Protein Length
Partial
Purity
>95% as determined by SDS-PAGE.
Research Area
Cancer
Source
E.coli
Species
Homo sapiens (Human)
Target Names
Uniprot No.
Target Background
Function
This receptor for TNFSF13/APRIL and TNFSF13B/TALL1/BAFF/BLYS binds both ligands with similar high affinity. It mediates calcineurin-dependent activation of NF-AT, as well as activation of NF-kappa-B and AP-1. TNFRSF13B is involved in stimulating B- and T-cell function and regulating humoral immunity.
Gene References Into Functions
- Expression patterns of BAFF and its receptor TACI differ according to lupus nephritis class. PMID: 29087261
- The p.G76S gain-of-function mutation on the TNFRSF13B gene is responsible for familial or sporadic immune thrombocytopenia. PMID: 28834165
- BAFF-induced processing of BAFFR regulates BAFF-mediated B cell responses in a TACI-dependent manner. PMID: 28249164
- Results suggest that TACI A181E heterozygosity results in TACI haploinsufficiency with increased susceptibility to pneumococcal infection PMID: 27609654
- This genetic polymorphism is associated with hypogammaglobulinemia and systemic lupus erythematosis in a family with common variable immunodeficiency disorder PMID: 26623716
- 11% of common variable immunodeficiency patients and 13% of antibody deficiency syndromes patients carried at least one mutated TNFRSF13B allele. PMID: 27123465
- Serum levels are not associated with disease activity in MPO-ANCA-associated renal vasculitis PMID: 25567522
- This review aims to provide insights into the genetics underlying CVID and particularly to outline the role of TACI and its relative contribution to the development of CVID-like phenotypes in humans. PMID: 26096648
- The C104R mutation was associated with common variable immunodeficiency and IgG subclass deficiency. PMID: 26727773
- TNFRSF13B hemizygosity does not recapitulate autoimmune features of common variable immune deficiency -associated C104R and A181E TNFRSF13B mutations, which likely encode dominant negative products, but instead reveals selective TACI haploinsufficiency at later stages of B-cell development. PMID: 26100089
- Common variable immune deficiency patients with heterozygous mutations in TACI alleles have increased susceptibility to autoimmune diseases. PMID: 25866827
- The study demonstrated that there is remarkable interindividual variability of TACI expression in chronic lymphocytic leukemia, although the majority of patients display low to undetectable TACI. PMID: 25950010
- Variants of TNFRSF13B were associated with common variable immunodeficiency. PMID: 26122175
- Only Transmembrane Activator and CAML Interactor (TACI) correlates with the MMC's capability to ligate BAFF. Additionally, the level of expression of TACI correlates with the level of the MMC's BM dependency PMID: 25723853
- Data show significant differences in expression of tumor necrosis factor family (BAFF) receptors BAFF-R, BCMA and TACI in patients with and without anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies. PMID: 25301447
- Although the transcriptional controls for alternative splicing of TACI isoforms remain unknown, differential signals via isoforms may control plasma-cell generation. PMID: 25631768
- In conclusion, we confirmed the prognostic significance of soluble BLyS levels with regard to TFT in CLL patients, and, more importantly, we showed for the first time that sTACI is a powerful prognostic marker, related to parameters of disease activity PMID: 25162001
- The released sTACI is an immunoregulator that shares decoy functions with atacicept. It reflects systemic and compartmentalized B cell accumulation and activation. PMID: 25505277
- This genetic polymorphism is associated with lung function in Hutterites, who are a founder population of European descent in North America PMID: 23932459
- TNFRSF13B/TACI defects alone do not result in CVID but may be also found frequently in distinct clinical phenotypes, including benign lymphoproliferation and IgG subclass deficiencies. PMID: 23956760
- TACI mutations enable autoimmune complications in common variable immune deficiency. PMID: 24051380
- Intracellular and extracellular TACI expression was defective for B cells of all subjects with mutations. PMID: 23237420
- A significant association of TNFRSF13B gene mutations was observed in common variable immunodeficiency patients. PMID: 22884984
- Naturally occurring mutation affecting the MyD88-binding site of TNFRSF13B impairs triggering of class switch recombination. PMID: 23225259
- Segregation analysis of a kindred shows that inheriting single or double copy of the Cys104Arg mutation does not necessarily consign an individual to common variable immunodeficiency (CVID). PMID: 22983507
- Two pediatric Italian male siblings were affected with hypogammaglobulinemia and recurrent respiratory and gastrointestinal infections in association with a novel compound heterozygous I87N/C104R TACI mutation. PMID: 22627058
- Three SNPs located in TNFRSF13B on 17p11.2 or nearby were significantly associated with IgG level. PMID: 22673310
- Data suggest a different impact of TACI mutations, from hypogammaglobulinemia in children to autoimmune disease in adulthood. PMID: 22697072
- The identification of two novel mutations in TNFRSF13B, including one, S231R, affecting the highly conserved THC domain PMID: 22076597
- We conclude that mutations in TACI are the contributing factors for asthma symptoms in Swedish children, although the mechanisms still remain elusive. PMID: 21850030
- Our data provide further evidence that TNFRSF13B/TACI alterations are not causative of common variable immunodeficiency PMID: 21547394
- Signals from TLR9, TACI, and CD40 are integrated to promote B-cell activation and differentiation. PMID: 21741080
- Primary leukemia B-cell precursors aberrantly express receptors of the BAFF-system, BAFF-R, BCMA, and TACI PMID: 21687682
- We have examined the function of TACI coding variants that have been described in patients with common variable immunodeficiency PMID: 21419480
- In patients with Smith-Magenis syndrome with only 1 TACI allele, we found decreased B-cell expression of TACI, reduced binding of a proliferation-inducing ligand, and decreased TACI-induced expression of activation-induced cytidine deaminase mRNA. PMID: 21514638
- Mutations result in impaired B cell response through haploinsufficiency PMID: 20889194
- TACI expression on CD19+ B cells was up-regulated in patients with lupus nephritis PMID: 20974656
- MyD88 controls a B cell-intrinsic, TIR-independent, TACI-dependent pathway for immunoglobulin diversification PMID: 20676093
- The TNFRSF13B A181E mutation is associated with a very heterogeneous clinical presentation along with variability in B-cell numbers and amount of TACI protein on memory B cells in Common Variable ImmunoDeficiency PMID: 20156508
- Novel mutations identified in this study support the notion of a crucial role for TACI in B cell differentiation PMID: 19629655
- Expression of BCMA, TACI, and BAFF-R by multiple myeloma cells support cell growth and survival. PMID: 14512299
- TACI(hi) myeloma cells displayed a mature plasma cell gene signature, indicating dependence on the BM environment. In contrast, the TACI(lo) group had a gene signature of plasmablasts, suggesting an attenuated dependence on the BM environment PMID: 15827134
- 4 of 19 unrelated individuals with common variable immunodeficiency and 1 of 16 individuals with IgA deficiency had a missense mutation in one allele of TNFRSF13B PMID: 16007086
- Identified homozygous and heterozygous mutations in TNFRSF13B, encoding TACI, in 13 individuals with common variable immunodeficiency PMID: 16007087
- Review. Short-lived antibody forming cell populations and their proliferating progenitors express a TACI-predominant signature. PMID: 16919470
- The TACI inhibited HRS cell accumulation in vitro and might attenuate HL expansion in vivo. PMID: 16960154
- Simultaneous binding of TACI and HSPG on B cells with APRIL is crucial for IgA production PMID: 17119122
- TACI-specific signaling inhibits both B cell activating factor of the TNF family receptor (BAFF-R) and CD40-enhanced antibody production from peripheral blood B cells in vitro, although TACI-specific signaling directly induces mild B cell apoptosis. PMID: 17154264
- This review defines the exact contribution of TACI receptor stimulation by specific triggers in vitro, enabling us to better understand the complex, context-dependent responses initiated by TACI in vivo. PMID: 17171762
- Role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency. PMID: 17392797
Database Links
Involvement In Disease
Immunodeficiency, common variable, 2 (CVID2); Immunoglobulin A deficiency 2 (IGAD2)
Subcellular Location
Membrane; Single-pass type III membrane protein.
Tissue Specificity
Highly expressed in spleen, thymus, small intestine and peripheral blood leukocytes. Expressed in resting B-cells and activated T-cells, but not in resting T-cells.
Quick Inquiry
Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
